DIGITALED
3.8.2021 13:02:10 CEST | Business Wire | Press release
Today, DigitalEd announces a growth investment from PSG; a leading growth equity firm partnering with middle-market software and technology-enabled services companies. DigitalEd provides a SaaS-based digital learning platform called Möbius, focusing on science, technology, engineering and mathematics (STEM) education. PSG is DigitalEd’s sole outside investor. Financial terms were not disclosed.
DigitalEd was founded in 2018 with a simple and resonant mission - to shape the world through digital learning. DigitalEd provides individual learning, in a shared world, allowing students to acquire knowledge at a guided, self-defined pace. DigitalEd currently supports over 300 educational institutions worldwide, administering over 20 million tests and assignments, supporting online learning for world-class universities, institutes of technology, and community colleges.
Möbius is an innovative and comprehensive platform for STEM education. The platform is designed to reduce the time educators need to spend on administrative tasks, traditionally required for course preparation and grading, allowing them to maximize time spent teaching and interacting with students. The platform focuses on student success by providing educators with high-quality course content created by STEM curriculum experts. Möbius can deliver coursework and monitor student performance with analytics. For students, Möbius provides an interactive digital learning environment that can be accessed anytime, anywhere, providing sophisticated automatic marking and immediate, focused student feedback.
“We are extremely proud of the ongoing adoption of Möbius, and how it has allowed online education to enhance and improve traditional education,” said Jim Cooper, Founder and CEO of DigitalEd. “We believe the PSG team understands and is committed to our founding vision. In our view, they are a perfect partner for DigitalEd, as we seek to continue to expand the Möbius platform to empower educators by both measuring and improving the learning experience.”
“We believe DigitalEd has a robust and highly scalable platform which is uniquely positioned for growth amid the rising demand for both e-learning tools and STEM education,” said Chris Andrews, Principal at PSG. “We look forward to working alongside Jim, Christina and the rest of DigitalEd’s talented team in an effort to accelerate the company’s growth through product innovation, strategic go-to-market initiatives and continued focus on user experience.”
“Everything we do at DigitalEd is grounded in optimizing the experiences and successes of students,” said Christina Perdikoulias, President of DigitalEd. “We are excited to partner with PSG and continue our commitment to providing high-quality, individualized and accessible education at scale.”
Stikeman Elliot LLP and Weil, Gotshal & Manges LLP served as legal advisors to PSG. Gowlings WLG, Grant Thornton LLP and Tyton Partners served as advisors to DigitalEd.
About DigitalEd
DigitalEd is a cloud-based software company devoted to improving student educational success. At DigitalEd, we have used our beliefs, values and core pillars of software development to build the Möbius platform; an innovative and comprehensive learning platform for Science, Technology, Engineering and Mathematics.
To learn more about DigitalEd, visit: www.digitaled.com
About PSG
PSG is a growth equity firm that partners with middle-market software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 80 companies and facilitated over 325 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City and London. To learn more about PSG, visit www.psgequity.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210803005210/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom